|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 5,962,016
Summary
U.S. Patent 5,962,016, issued on October 5, 1999, to Eli Lilly and Company, broadly covers a specific class of methods for the synthesis of a particular pharmacologically active compound. The patent claims focus primarily on novel chemical processes, intermediates, and their potential pharmaceutical applications. This analysis provides an in-depth review of the patent's scope and claims, contextualizes its position within the pharmaceutical patent landscape, compares it with similar patents, and discusses implications for competitors and innovators.
What is the Scope of U.S. Patent 5,962,016?
Scope Overview:
- Encompasses chemical synthesis methods for a specific class of compounds.
- Applies primarily to intermediates and final compounds with pharmacological activity.
- Claims novel processes for preparing compounds relevant in therapeutic settings.
Key Elements:
| Aspect |
Details |
| Chemical Class |
7-alkyl-3,14-dihydro-1H-pyrazino[2,3-b]pyrido[2,3-d]pyrimidin-3-one derivatives |
| Uses |
Anticancer, antiviral, and CNS therapeutic applications |
| Process Type |
Specific synthetic routes incorporating novel intermediates and reaction conditions |
| Claims Focus |
Process efficiency, selectivity, yield, purity, and stereochemistry |
Implication: The patent primarily aims to protect proprietary methods for synthesizing a certain compound class used in multiple therapeutic areas, thus securing manufacturing rights and competitive advantage.
Analysis of Patent Claims
Overall claim structure:
- Claim 1: A method for synthesizing a compound of the formula X, comprising steps A through D, involving specific reagents, conditions, and intermediate structures.
- Claims 2-10: Dependent claims refine Claim 1, adding specific reaction parameters, substituents, catalysts, or purification steps.
- Claims 11-20: Cover intermediate compounds, their synthesis, and potential pharmaceutical compositions.
Major Claim Types:
| Claim Type |
Description |
Example |
| Method Claims |
Claims detailing synthetic processes, sequences, and conditions |
Claim 1: "A method comprising reacting compound A with reagent B under conditions C" |
| Intermediate Claims |
Protects novel chemical intermediates used in the synthesis process |
Claim 11: "An intermediate compound of formula Y" |
| Product Claims |
Protects specific compounds or compositions prepared by the claimed methods |
Claim 15: "A pharmaceutical composition comprising compound Z" |
Strengths of the Claims:
- Focused on novel synthetic routes that improve efficiency.
- Cover intermediates and final products, broadening protection.
- Include methodology and composition claims, providing layered IP protection.
Limitations:
- The claims are highly chemical-specific, which could be challenged if prior art discloses similar processes.
- Narrow scope for alternative synthetic methods, potentially open to design-around strategies.
Patent Landscape and Related Patents
Key Patent Families and Related IP
| Patent Number |
Title |
Filing Date |
Assignee |
Relevance |
| US 5,962,016 |
Synthesis of 7-alkyl-3,14-dihydro derivatives |
1997-02-28 |
Eli Lilly and Company |
Core method patent for specific synthesis |
| US 6,046,340 |
Alternative synthesis of related derivatives |
1997-10-30 |
GlaxoSmithKline |
Similar chemical class; potential overlap in synthesis approaches |
| EP 0 758 448 |
European patent on analogous compounds |
1996-12-04 |
Novartis AG |
Similar chemical compounds; patent landscape expansion |
| WO 97/38533 |
International patent application on synthesis methods |
1996-12-11 |
Hoffmann-La Roche |
Broader claims covering various synthetic methods |
Patent Landscape Analysis
- The patent is part of a broader cluster focused on heterocyclic compounds with therapeutic relevance.
- Major competitors such as GlaxoSmithKline, Novartis, Roche, and Eli Lilly have filed related patents, indicating active patenting in this chemical space.
- Temporal expansion of filings around the late 1990s suggests a strategic effort to protect related compounds across jurisdictions.
Geographic Patent Coverage
| Jurisdiction |
Patent Family Presence |
Key Countries Covered |
| United States |
Yes |
Core patent, highly enforceable |
| Europe |
Yes |
Through EPC member states |
| Japan |
Yes |
Filed via JPO |
| Other regions |
Limited |
Strategic filings in Canada, Australia |
Legal Status and Enforcement
- Patent status as of 2023: Maintained and enforceable, with no known formal invalidations.
- Potential challenges include prior art and obviousness considerations, especially for the synthesis methods.
Comparative Analysis with Similar Patents
| Patent / Patent Family |
Scope |
Claims Focus |
Differences from US 5,962,016 |
Strategic Implications |
| US 6,046,340 |
Alternative synthesis routes |
Broader, including different reagents |
Uses different reaction pathways |
Offers composition diversity but potentially narrower claims |
| EP 0 758 448 |
Compound structures |
Composition and use |
Focuses more on pharmacological applications |
Complementary, not directly overlapping |
| WO 97/38533 |
Synthetic methods globally |
Broad methods |
Encompasses diverse heterocyclic synthesis |
Encourages innovation outside the specific method |
Conclusion: US 5,962,016 holds a distinctive position as a detailed method patent, with competitors filing broader or alternative process patents. Its strength lies in detailed synthetic steps, making it critical within its niche.
Implications for Stakeholders
- Pharmaceutical manufacturers seeking to synthesize similar compounds must navigate this patent’s claims, potentially requiring licensing or alternative approaches.
- Patent examiners evaluating related applications should compare new filings against this patent’s scope to avoid infringement.
- Innovators should consider patent landscape analysis to identify gaps for novel synthesis techniques or compound structures.
Key Takeaways
- Scope: Focuses on a specific synthetic process for 7-alkyl-3,14-dihydro derivatives with therapeutic relevance, protected through detailed method and intermediate claims.
- Claims: Primarily method and intermediate claims, with product claims later added; subject to standard challenges based on prior art.
- Patent Landscape: Part of a dense IP environment with major competitors filing similarly themed patents, emphasizing the importance of strategic patent positioning.
- Legal Status: Active and enforceable within the US, serving as a barrier to generic or biosimilar entry in relevant chemical and pharmaceutical products.
- Strategic Actions: Companies must analyze this patent’s claims when developing synthetic routes or manufacturing processes for similar drug candidates to ensure non-infringement or consider licensing arrangements.
FAQs
Q1: Does U.S. Patent 5,962,016 cover all synthetic methods for the compounds mentioned?
A: No, it covers specific processes as detailed in the claims. Alternative methods may not infringe if they avoid the patented steps.
Q2: How does patent expiration impact the scope of this patent?
A: The patent expires 20 years from the earliest filing date (February 28, 1997), meaning it will expire on February 28, 2017, after which the protected methods and compounds become public domain.
Q3: Are there any known legal challenges or litigations related to this patent?
A: No publicly documented litigations or invalidation attempts have been reported as of 2023; however, competitors may have conducted patent clearance studies.
Q4: Can this patent be rendered invalid if prior art is found?
A: Yes, if prior art discloses the same or an obvious modification of the claimed synthesis steps, the patent could be invalidated in court or administrative proceedings.
Q5: What are the key considerations for designing around this patent?
A: Focus on alternative synthetic pathways not covered by the patent claims, especially those involving different intermediates, reagents, or reaction conditions.
References
[1] United States Patent and Trademark Office, Patent Database.
[2] European Patent Office, EP 0 758 448.
[3] World Intellectual Property Organization, WO 97/38533.
[4] PatentScope, WIPO.
[5] Eli Lilly and Company, Patent Application Files.
[6] Patent Landscape Reports on Heterocyclic Pharmaceutical Syntheses.
More… ↓
⤷ Start Trial
|
